

28th July, 2023

**BSE Limited** 

P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635 **National Stock Exchange of India Limited** 

Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA

Sub: Regulation 29 and Regulation 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Unaudited Financial Results (Standalone and Consolidated) for the quarter ended  $30^{th}$  June, 2023

**Board Meeting on 3rd August, 2023** 

Dear Sir / Madam,

Pursuant to Regulation 29 and 50 of the Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Thursday, 3<sup>rd</sup> August, 2023, *inter alia* to consider the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter ended 30<sup>th</sup> June, 2023.

In this regard, we write to inform you that the 'Trading Window' for dealing in the securities of the Company, which has been closed from Saturday, 1<sup>st</sup> July, 2023 will remain closed till Saturday, 5<sup>th</sup> August, 2023 (both days inclusive).

Thanking you,

Yours truly,

For Piramal Pharma Limited

Tanya Sanish Company Secretary